Dr. Omid Rabbani is a board certified adult neurologist who practices in Ventura County, California. Since joining the practice of Dr. Henry Tang in August of 2012, he provides comprehensive general neurological care in the cities of Simi Valley and Thousand Oaks. His clinical interests include Epilepsy/Seizures, Headaches, Back pain, Memory disorders/Dementia and Stroke. Dr. Rabbani also provides electrodiagnostic testing in the office including EEGs and EMG/Nerve Conduction Studies.

Dr. Rabbani comes to Ventura County after practicing general neurology in Naples, Florida for five years. He completed his undergraduate studies at the University of Florida and graduated with Highest Honors in the interdisciplinary major of Neurobiological Sciences. Dr. Rabbani had an early interest in neurological research while in college and was able to publish three medical articles before beginning medical school. Additionally, he obtained an undergraduate research grant in 1997 from the American Foundation for Aging Research. In 2003, Dr. Rabbani graduated from The Chicago Medical School/FUHS and then began his medical Internship and Neurology Residency at The University of Florida. In 2004, he received a Shands Hospital Star Certificate for dedication to patient care. After completing his Neurology Residency in 2007, Dr. Rabbani joined a busy and successful multispecialty private group practice. Expanding on his interest in medical research, he was involved in over sixteen clinical research studies during the past few years. He is a member of the American Academy of Neurology.

Although born in Iran, Dr. Rabbani and his family moved to the United States in 1979. He and his wife Julie were both raised in Orlando, Florida and met through their mutual background of the Baha’i Faith religion. Julie is pursuing her career in fashion design in the Los Angeles area. Aside from their careers, Dr. Rabbani and his wife keep themselves busy raising their two young sons, Nabil and Aiden. When not working, Dr. Rabbani enjoys playing basketball, exercising, watching movies, playing piano and traveling.

M.D. Program, 1999-2003
Finch University of Health Sciences/The Chicago Medical School, North Chicago, IL

Interdisciplinary Studies Major in Neurobiological Sciences, 1994-1998
B.S., May 1998, Highest Honors
The University of Florida, Gainesville, FL
Thesis: The Neuroprotective Effects of Estrogen on Medial Septal Cholinergic Neurons
Following Fimbria-Fornix Lesion in the Female Sprague-Dawley Rat

Neurology Residency, 2004-2007
University of Florida/Shands Hospital, Gainesville, FL
Program Director: Hubert Fernandez, M.D.
Research Mentor:  Stephen Nadeau, M.D.

Internship in Internal Medicine, 2003-2004
University of Florida/Shands Hospital, Gainesville, FL
Program Director: N. Lawrence Edwards, M.D.

State of California

• Teaching Assistant for Medical Students in first year Medical Neuroscience Course, University of Florida, 1/04 Course Director: Louis Ritz, Ph.D.
  
  
• MDA Clinic Volunteer, Shands Medical Plaza, 2004-6
  
  
• Student Experiences and Rotations in Community Health (SEARCH) program sponsored by the Illinois Area Health Education Center, participant in program that offers students training opportunities at community/migrant health centers located in urban/rural areas of Illinois, 8/01
  
  
• Local Spiritual Assembly of the Baha’is of North Chicago, member, 2000-2001
  
  
• Local Spiritual Assembly of the Baha’is of Collier County, Naples, FL, member, 2009- 2011
  
  
• Chicago Medical School Health Care Project, volunteer in free clinic for the homeless, 3/01
  
  

American Academy of Neurology, member, 2004-present

• Hedna, V.S.; Jain, S.; Rabbani, O. and S.E. Nadeau. (2011) Mechanisms of arm paresis in middle cerebral artery distribution stroke. (pending)
  
  
• Rabbani, O.; Bowen, L.E.; Watson, R.T.; Valenstein, E. and M.S. Okun. (2004) Alien limb syndrome and moya-moya disease. Movement Disorders, 19(11):1317-20.
  
  
• Shi, J.; Panickar, K.S.; Yang, S.H.; Rabbani, O.; Day, A.L. and J.W. Simpkins. (1998) Estrogen attenuates over-expression of beta-amyloid precursor protein messenger RNA in an animal model of focal ischemia. Brain Research, 810(1-2): 87-92.
  
  
• Simpkins, J.W.; Rabbani, O.; Shi, J.; Panickar, K.S.; Green, P.S. and A.L. Day. (1998) A system for the brain-enhanced delivery of estradiol: an assessment of its potential for the treatment of Alzheimer’s disease and stroke. Die Pharmazie, 53(8): 505-11.
  
  
• Rabbani, O.; Panickar, K.S.; Rajakumar, G.; King, M.A.; Bodor, N.; Meyer, E.M. and J.W. Simpkins. (1997) 17 beta-estradiol attenuates fimbrial lesion-induced decline of ChAT-immunoreactive neurons in the rat medial septum. Experimental Neurology, 146(1): 179-86.
  
  

• A Randomized Double Blind, Placebo Controlled of XXX in Subjects Beginning Treatment within Six Hours of the Onset of Acute Ischemic Stroke.
  
  
• A Phase II, Randomized, Open Label, Safety and Tolerability Trial Comparing XXX with Routine Care in Patients with Chronic Painful Diabetic Peripheral Neuropathy.
  
  
• A Randomized Controlled, Open Label, Parallel, Group Study to evaluate the Effect of Regularly Scheduled Neutralized Antibody Testing on Treatment Patterns VS. usual Care in High Dose Interferon Treated Subjects.
  
  
• A Double Blind, Randomized, Placebo Controlled, Parallel Group Multicenter Phase IIb/III Study to Assess the Efficacy and Safety of XXX in Acute Ischemic Stroke.
  
  
• A Double Blind, Placebo Controlled, Randomized Parallel Group Safety, Efficacy and Dose Response Trial of Two Different Dose Levels of XXX in Patients with Signs and Symptoms of Acute Ischemic Stroke,.
  
  
• A Randomized, Multicenter, Placebo-Controlled and Active Reference (XXX) Comparison Study to Evaluate the Efficacy and Safety of YYY in Subjects with Relapsing-Remitting Multiple Sclerosis.
  
  
• A Randomized, Double Blind, Double Dummy Placebo Controlled, Crossover Study to Evaluate the efficacy of XXX versus YYY for the acute treatment of migraine when administered during the moderate to severe pain phase of the migraine.
  
  
• A Multi-Center, Placebo-Controlled, Double-Blind Trial To Examine the Safety and Efficacy of XXX in the Treatment of Psychosis in Parkinson’s Disease
  
  
• Multicenter, Double-blind, Randomized, Paralled-group, Monotherapy, Active-Control Study to Determine the Efficacy and Safety of XXX versus YYY in Patients with Relapsing-Remitting Multiple Sclerosis.
  
  
• JCV Antibody Program in Patints with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX.
  
  
• A Multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of XXX injection 40 mg administered three times a week compared to placebo in a double-blind design.
  
  
• A Double-blind, Placebo Controlled, Randomized, Multicenter Study to Assess the Safety and Clinical Benefit of XXX as an Add on Therapy to Stable Dose of Dopamine Agonists in the Treatment of Early Parkinson’s Disease.
  
  
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of XXX in Patients With Mild to Moderate Alzheimer’s Disease.
  
  
• A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XXX and YYY in Parkinson’s Disease Subjects with Motor Fluctuations
  
  
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study To Evaluate The Efficacy And Safety Of XXX In Patients With Mild To Moderate Alzheimer’s Disease
  
  
• A Phase 3, 12-Week, Double-Blind, Placebo-Controlled Efficacy and Safety Study of XXX in Subjects with Moderate to Severe Parkinson’s Disease
  
  

Undergraduate Student Grant, American Foundation for Aging Research, 1997.

Shands Hospital Star Certificate for Dedication to Patient Care, 2004

The American Board of Psychiatry and Neurology
The Medical Board of California